Healthy Clinical Trial
Official title:
Hormone Replacement in Young Women With Premature Ovarian Failure
The human ovary produces male sex hormones (androgen) and female sex hormones (estrogen).
Currently, androgen is not included in hormone replacement therapy for women with premature
ovarian failure. Present hormone replacement therapy (HRT) was designed to treat women who
experience ovarian failure at menopause (around the age of 50). However, 1% of women will
experience premature failure of the ovaries before the age of 40. There have been no studies
conducted to determine proper hormone replacement therapies for these younger women. Some
research suggests that the usual menopausal hormone replacement therapy is not adequate to
protect young women with premature ovarian failure from developing osteoporosis. Women with
premature ovarian failure have abnormally low levels of androgens circulating in their
blood. This may contribute to the increase risk for osteoporosis.
This study will compare two treatment plans for women with premature ovarian failure.
Treatment plan one will be physiological estrogen hormone replacement. Treatment plan two
will be physiological estrogen hormone replacement plus androgen. The study will attempt to
determine which plan is more beneficial to women in relation to osteoporosis and heart
disease.
The hormones will be contained in patches and given by placing the patches against the
patient's skin. The patches were designed to deliver the same amount of hormone as would be
normally produced by the ovary in young women.
The success of the treatment will be measured by periodically checking the density of
patient's bone in the leg (femoral neck bone) . Researchers will take an initial (baseline)
measurement of bone density before beginning treatment and then once a year, for 3
additional years, during treatment. The study will also consider bone density of the spine,
bone turnover, heart disease risk factors, and psychological state.
Status | Completed |
Enrollment | 250 |
Est. completion date | October 2006 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 32 Years |
Eligibility |
- INCLUSION CRITERIA: Patients with karyotypically normal spontaneous premature ovarian failure (as defined by screening protocol 91-CH-0127, i.e. women who have at least 4 months of amenorrhea, two FSH levels above 40 mIU/ml, at least one month apart, and a normal 46, XX karotype, diagnosed with premature ovarian failure prior to the age of 40) who are between the age of 18 and 42 years will be candidates. EXCLUSION CRITERIA: General: Smokers (more than 2 cigarettes per day). Alcohol users (more than 2 drinks of alcohol per day). Body mass index (BMI, kg/m(2)) greater than or equal to 30 and less than or equal to 19. Previous history of hip fracture or other active hip pathology. Abnormalities of the hip precluding the assessment of bone mineral density. Major dermatologic disorders, or a history of skin sensitivity to adhesive bandages, tape or transdermal matrix patches. Hirsutism score greater than 8. Acne score greater than 1. Hysterectomy Baseline free testosterone (FT) levels above the normal range (greater than 6.3 pg/ml in our current essay) and/or SHBG levels less than 36 nmol/L. Medical use: Any prior treatment in the past 6 months known to affect bone other than estrogen (i.e., calcitonin, biphosphonates, fluoride, anabolic steroids, testosterone, or herbal therapy that contains androstenedione, and DHEA). Current and/or past use of: diuretics, anticoagulants (heparin, Coumadin), glucocorticoid drugs, gonadotropin-releasing hormone agonist or antagonist therapy, chemotherapy. Medical history of: Anorexia nervosa, hyperprolactinemia, insulin-dependent diabetes, Cushing's syndrome, gastrectomy, osteogenesis imperfecta, mastocytosis, rheumatoid arthritis, long-term parenteral nutrition, hemolytic anemia, hemochromatosis and thalassemia, ankylosing spondylitis, multiple myeloma, Vitamin D deficiency, Paget's disease, primary hyperparathyroidism, hyperthyroidism, hypothyroidism, any cancer or any other major illness. Contraindications to hormone replacement therapy: Thromboembolic event associated with previous estrogen use History of endometrial cancer or hyperplasia History of breast cancer Hypertriglyceridemia (fasting triglyceride levels greater than 500 mg/dL) LDL greater than 190mg/dl Patients taking "statins" Serum Alkaline phosphatase greater than or equal to 2X the upper limit of normal Serum GGT greather than or equal to 2X the upper limit of normal Abnormal values on two or more hepatic panel tests Undiagnosed Vaginal Bleeding Known sensitivity to agents Note: We will include patients with premature ovarian failure on antidepressant medications, since today's most common antidepressant medication (Prozac) does not have a major import on cognitive function. However, we will note whether they are on these medications. CONTROL SELECTION CRITERIA: Healthy non-pregnant regularly menstruating women (cycles between 21 and 35 days), non-smokers, non-alcohol users, under no medications, using non-hormonal contraceptive methods (i.e. barrier methods of contraception, or sterilization) and with no intention to conceive within the following 3 years. |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Child Health and Human Development (NICHD) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am. 1998 Dec;27(4):989-1006. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |